All In Biotech

Drug Trial Radar · NCT05883748

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. Randomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

230

Planned (sponsor's estimate)

Start

Aug 31, 2023

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Disc Medicine, IncIndustry
Sponsor type
Industry
First posted
Jun 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

Conditions

  • Erythropoietic Protoporphyria

Interventions

  • DISC-1459Drug

    DISC-1459 dose level 1

  • DISC-1459Drug

    DISC-1459 dose level 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: up to 5 Years
  2. Incidence of clinically abnormal vital signsTime frame: up to 5 Years
  3. Incidence of clinically abnormal physical examTime frame: up to 5 Years
  4. Incidence of abnormal laboratory test resultsTime frame: up to 5 Years
  5. Assessment of Patient Health Questionnaire (PHQ-8)Time frame: up to 5 Years
  6. Assessment of C-SSRSTime frame: up to 5 Years

Locations

26 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama Hospital

    Birmingham, Alabama

  • University of California San Francisco

    San Francisco, California

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • MetroBoston Clinical Partners

    Boston, Massachusetts

  • Mount Sinai Hospital

    New York, New York

  • Atrium Health Wake Forest Baptist

    Winston-Salem, North Carolina

  • Remington-Davis Clinical Research

    Columbus, Ohio

  • Einstein Medical Center

    Philadelphia, Pennsylvania

  • University of Texas

    Galveston, Texas

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • UZ Leuven

    Leuven, Belgium

  • CHU de Nantes - Hôtel Dieu, Service de dermatologie

    Nantes, France, France

  • Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard

    Paris, France, France

  • Charité - Universitätsmedizin Berlin, Institute of Allergology

    Berlin, Germany, Germany

  • Klinikum Chemnitz gGmbH

    Chemnitz, Saxony, Germany

  • Children's Health Ireland (CHI)

    Dublin, Ireland

  • Instituto Dermatologico San Gallicano Istituti Fisioterapici Ospitalieri IRCCS

    Roma, Italy

  • Erasmus MC

    Rotterdam, Netherlands

  • Hospital Clinic de Barcelona

    Barcelona, Spain, Spain

  • Karolinska University Hospital

    Stockholm, Sweden, Sweden

  • Photobiology Unit, Salford Royal Hospital

    Salford, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust

    London, England, United Kingdom

  • Clinical Research Centre, Ninewells Hospital & Medical School , NHS Tayside

    Dundee, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.